Shield Therapeutics drops as CFO exits and Medicaid concerns weigh
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported…
proactiveinvestors.co.uk

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
1 signal unavailable — limited data for this stock
Trend
+0.3% vs SMA 50 · +65.5% vs SMA 200
Momentum
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2023 | $1.4B $1.4B–$1.4B | — | -$1.05 | — | — | Low1 |
FY2024 | $1.5B $1.5B–$1.5B | ▲ +5.4% | -$1.47 | — | ±2% | Moderate3 |
FY2025 | $1.6B $1.5B–$1.6B | ▲ +4.4% | -$1.27 | — | ±2% | Low2 |
Dividend per payment — last 8 periods
No institutional holdings data available.
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported…

No description available.